

References

1. Glezen WP, Taber LH, Frank AL, Kasel JA. Risk of primary infection and reinfection with respiratory syncytial virus. *Am J Dis Child.* 1986;140:543-546.
2. Eriksson M, Bennet R, Rotzen-Ostlund M, von Sydow M, Wirgart BZ. Population-based rates of severe respiratory syncytial virus infection in children with and without risk factors, and outcome in a tertiary care setting. *Acta Paediatr.* 2002;91:593-598.
3. Wang EE, Law BJ, Stephens D. Pediatric Investigators Collaborative Network on Infections in Canada (PICNIC) prospective study of risk factors and outcomes in patients hospitalized with respiratory syncytial viral lower respiratory tract infection. *J Pediatr.* 1995;126:212-9.
4. Hall CB. Respiratory syncytial virus and parainfluenza virus. *N Engl J Med.* 2001;344:1917-1928.
5. Shay DK, Holman RC, Newman RD, Liu LL, Stout JW, Anderson LJ. Bronchiolitis - associated hospitalizations among US children, 1980-1996. *JAMA.* 1999;282:1440-1446.
6. American Academy of Pediatrics. Respiratory Syncytial Virus. In: Pickering LK, ed. *2000 Red Book: Report of the Committee on Infectious Diseases.* 25th ed. Elk Grove Village, IL: American Academy of Pediatrics; 2000:484.
7. Perlstein PH, Kotagal UR, Bolling C, et al. Evaluation of an evidence-based guideline for bronchiolitis. *Pediatrics.* 1999;104:1334-1341.
8. Committee on Infectious Diseases. Reassessment of the indications for ribavirin therapy in respiratory syncytial virus infections. *Pediatrics.* 1996;97:37-140.
9. Flores G, Horwitz RI. Efficacy of beta2-agonists in bronchiolitis: a reappraisal and meta-analysis. *Pediatrics.* 1997;100:233-239.
10. Kellner JD, Ohlsson A, Gadomski AM, Wang EE. Bronchodilators for bronchiolitis. *Cochrane Database Syst Rev.* 2000;CD001266.
11. Garrison MM, Christakis DA, Harvey E, Cummings P, Davis RL. Systemic corticosteroids in infant bronchiolitis: A meta-analysis. *Pediatrics.* 2000;105:E44.
12. American Academy of Pediatrics Committee on Infectious Diseases and Committee of Fetus and Newborn. Prevention of respiratory syncytial virus infections: indications for the use of palivizumab and update on the use of RSV-IGIV. *Pediatrics.* 1998;102:1211-1216.
13. Joffe S, Ray GT, Escobar GJ, Black SB, Lieu TA. Cost-effectiveness of respiratory syncytial virus prophylaxis among preterm infants. *Pediatrics.* 1999;104:419-427.
14. Lofland JH, O'Connor JP, Chatterton ML, et al. Palivizumab for respiratory syncytial virus prophylaxis in high-risk infants: a cost-effectiveness analysis. *Clin Ther.* 2000;22:1357-1369.
15. Carande-Kulis VG, Maciosek MV, Briss PA, et al. Methods for systematic reviews of economic evaluations for the Guide to Community Preventive Services. Task Force on Community Preventive Services. *Am J Prev Med.* 2000;18:75-91.
16. Centers for Disease Control. The Community Guide: Guide to Community Preventive Services. 1996. Web Page. Available at: http://www.thecommunityguide.org/PDFS/EC_ONEVAL_version 3.pdf. Last accessed October 14, 2002
17. Richardson WS, Wilson M, Moyer V, Naylor CD. Diagnosis - Clinical Manifestations of Disease . In: Guyatt G, Rennie D, eds. *User's Guide to the Medical Literature: A Manual for Evidence-Based Clinical Practice.* Chicago, Ill: American Medical Association; 2002:449-516.

18. West SL, King V, Carey TS, et al. *Systems to Rate the Strength of Scientific Evidence*. Evidence Report, Technology Assessment No. 47. Rockville, Md.: Agency for Healthcare Research and Quality. AHRQ Publication No. 02-E016; 2002.
19. Court SD. The definition of acute respiratory illnesses in children. *Postgrad Med J*. 1973;49:771-776.
20. Randolph AG, Wang EE. Ribavirin for respiratory syncytial virus lower respiratory tract infection. A systematic overview. *Arch Pediatr Adolesc Med*. 1996;150:942-947.
21. Klassen TP, Rowe PC, Sutcliffe T, Ropp LJ, McDowell IW, Li MM. Randomized trial of salbutamol in acute bronchiolitis. *J Pediatr*. 1991;118:807-811.
22. Menon K, Sutcliffe T, Klassen TP. A randomized trial comparing the efficacy of epinephrine with salbutamol in the treatment of acute bronchiolitis. *J Pediatr*. 1995;126:1004-1007.
23. Schuh S, Coates AL, Binnie R, et al. Efficacy of oral dexamethasone in outpatients with acute bronchiolitis. *J Pediatr*. 2002;140:27-32.
24. Can D, Inan G, Yendur G, Oral R, Gunay I. Salbutamol or mist in acute bronchiolitis. *Acta Paediatr Jpn*. 1998;40:252-255.
25. Rodriguez WJ , Gruber WC, Groothuis JR, et al. Respiratory syncytial virus immune globulin treatment of RSV lower respiratory tract infection in previously healthy children. *Pediatrics*. 1997;100:937-942.
26. Ahluwalia G, Embree J, McNicol P, Law B, Hammond GW. Comparison of nasopharyngeal aspirate and nasopharyngeal swab specimens for respiratory syncytial virus diagnosis by cell culture, indirect immunofluorescence assay, and enzyme-linked immunosorbent assay. *J Clin Microbiol*. 1987;25:763-767.
27. Chattopadhy D, Chatterjee R, Anand VK, Kumari S, Patwari AK. Lower respiratory tract infection in hospitalized children due to respiratory syncytial (RS) virus during a suspected epidemic period of RS virus in Delhi. *J Trop Pediatr*. 1992;38:68-73.
28. Eugene-Ruellan G, Freymuth F, Bahloul C, Badrane H, Vabret A, Tordo N. Detection of respiratory syncytial virus A and B and parainfluenzavirus 3 sequences in respiratory tracts of infants by a single PCR with primers targeted to the L-polymerase gene and differential hybridization. *J Clin Microbiol*. 1998;36:796-801.
29. Ong GM, Wyatt DE, O'Neill HJ, McCaughey C, Coyle PV. A comparison of nested polymerase chain reaction and immunofluorescence for the diagnosis of respiratory infections in children with bronchiolitis, and the implications for a cohorting strategy. *J Hosp Infect*. 2001;49:122-128.
30. Waner JL, Whitehurst NJ, Todd SJ, Shalaby H, Wall LV. Comparison of directigen RSV with viral isolation and direct immunofluorescence for the identification of respiratory syncytial virus. *J Clin Microbiol*. 1990;28:480-483.
31. Lozano J.M., Wang E. Bronchiolitis. *Clin Evid* . 2002;272-282.
32. Shaw KN, Bell LM, Sherman NH. Outpatient assessment of infants with bronchiolitis. *Am J Dis Child*. 1991;145:151-155.
33. Mulholland EK, Olinsky A, Shann FA. Clinical findings and severity of acute bronchiolitis. *Lancet*. 1990;335:1259-1261.
34. Cherian T, Steinhoff MC, Simoes EA, John TJ. Clinical signs of acute lower respiratory tract infections in malnourished infants and children. *Pediatr Infect Dis J*. 1997;16:490-494.

35. Saijo M, Ishii T, Kokubo M, Murono K, Takimoto M, Fujita K. White blood cell count, C-reactive protein and erythrocyte sedimentation rate in respiratory syncytial virus infection of the lower respiratory tract. *Acta Paediatr Jpn.* 1996;38:596-600.
36. Dawson KP, Long A, Kennedy J, Mogridge N. The chest radiograph in acute bronchiolitis. *J Paediatr Child Health.* 1990;26:209-211.
37. Dobson JV, Stephens-Groff SM, McMahon SR, Stemmler MM, Brallier SL, Bay C. The use of albuterol in hospitalized infants with bronchiolitis. *Pediatrics.* 1998;101:361-368.
38. Friis B, Eiken M, Hornsleth A, Jensen A. Chest X-ray appearances in pneumonia and bronchiolitis. Correlation to virological diagnosis and secretory bacterial findings. *Acta Paediatr Scand.* 1990;79:219-225.
39. Luchetti M, Casiraghi G, Valsecchi R, Galassini E, Marraro G. Porcine-derived surfactant treatment of severe bronchiolitis. *Acta Anaesthesiol Scand.* 1998;42:805-810.
40. Nasr SZ, Strouse PJ, Soskolne E, et al. Efficacy of recombinant human deoxyribonuclease I in the hospital management of respiratory syncytial virus bronchiolitis. *Chest.* 2001;120:203-208.
41. Rodriguez WJ , Gruber WC, Welliver RC, et al. Respiratory syncytial virus (RSV) immune globulin intravenous therapy for RSV lower respiratory tract infection in infants and young children at high risk for severe RSV infections: Respiratory Syncytial Virus Immune Globulin Study Group. *Pediatrics.* 1997;99:454-461.
42. Rodriguez WJ , Kim HW, Brandt CD, et al. Aerosolized ribavirin in the treatment of patients with respiratory syncytial virus disease. *Pediatr Infect Dis J.* 1987;6:159-163.
43. Roosevelt G, Sheehan K, Grupp-Phelan J, Tanz RR, Listernick R. Dexamethasone in bronchiolitis: a randomised controlled trial. *Lancet.* 1996;348:292-295.
44. Schuh S, Canny G, Reisman JJ, et al. Nebulized albuterol in acute bronchiolitis. *J Pediatr.* 1990;117:633-637.
45. Taber LH, Knight V, Gilbert BE, et al. Ribavirin aerosol treatment of bronchiolitis associated with respiratory syncytial virus infection in infants. *Pediatrics.* 1983;72:613-618.
46. Barry W, Cockburn F, Cornall R, Price JF, Sutherland G, Vardag A. Ribavirin aerosol for acute bronchiolitis. *Arch Dis Child.* 1986;61:593-597.
47. Chipps BE, Sullivan WF, Portnoy JM. Alpha-2A-interferon for treatment of bronchiolitis caused by respiratory syncytial virus. *Pediatr Infect Dis J.* 1993;12:653-658.
48. De Boeck K, Van der Aa N, Van Lierde S, Corbeel L, Eeckels R. Respiratory syncytial virus bronchiolitis: a double-blind dexamethasone efficacy study. *J Pediatr.* 1997;131:919-921.
49. Friis B, Andersen P, Brenoe E, et al. Antibiotic treatment of pneumonia and bronchiolitis. A prospective randomised study. *Arch Dis Child.* 1984;59:1038-1045.
50. Kjolhede CL, Chew FJ, Gadomski AM, Marroquin DP. Clinical trial of vitamin A as adjuvant treatment for lower respiratory tract infections. *J Pediatr.* 1995;126:807-812.
51. Kong XT, Fang HT, Jiang GQ, Zhai SZ, O'Connell DL, Brewster DR. Treatment of acute bronchiolitis with Chinese herbs. *Arch Dis Child.* 1993;68:468-471.
52. Kristjansson S, Lodrup Carlsen KC, Wennergren G, Strannegard IL, Carlsen KH. Nebulised racemic adrenaline in the treatment of acute bronchiolitis in infants and toddlers. *Arch Dis Child.* 1993;69:650-654.
53. Bertrand P, Aranibar H, Castro E, Sanchez I. Efficacy of nebulized epinephrine versus salbutamol in hospitalized infants with bronchiolitis. *Pediatr Pulmonol.* 2001;31:284-288.

54. Reijonen T, Korppi M, Pitkakangas S, Tenhola S, Remes K. The clinical efficacy of nebulized racemic epinephrine and albuterol in acute bronchiolitis. *Arch Pediatr Adolesc Med.* 1995;149:686-692.
55. Sanchez I, De Koster J, Powell RE, Wolstein R, Chernick V. Effect of racemic epinephrine and salbutamol on clinical score and pulmonary mechanics in infants with bronchiolitis. *J Pediatr.* 1993;122:145-151.
56. Schweich PJ, Hurt TL, Walkley EI, Mullen N, Archibald LF. The use of nebulized albuterol in wheezing infants. *Pediatr Emerg Care.* 1992;8:184-188.
57. Hickey RW, Gochman RF, Chande V, Davis HW. Albuterol delivered via metered-dose inhaler with spacer for outpatient treatment of young children with wheezing. *Arch Pediatr Adolesc Med.* 1994;148:189-194.
58. Cengizlier R , Saraclar Y, Adalioglu G, Tuncer A. Effect of oral and inhaled salbutamol in infants with bronchiolitis. *Acta Paediatr Jpn.* 1997;39:61-63.
59. Gadomski AM, Lichenstein R, Horton L, King J, Keane V, Permutt T. Efficacy of albuterol in the management of bronchiolitis. *Pediatrics.* 1994;93:907-912.
60. Gadomski AM, Aref GH, el Din OB, el Sawy IH, Khallaf N, Black RE. Oral versus nebulized albuterol in the management of bronchiolitis in Egypt. *J Pediatr.* 1994;124:131-138.
61. Goh A, Chay OM, Foo AL, Ong EK. Efficacy of bronchodilators in the treatment of bronchiolitis. *Singapore Med J.* 1997;38:326-328.
62. Ho L, Collis G, Landau LI, Le Souef PN. Effect of salbutamol on oxygen saturation in bronchiolitis. *Arch Dis Child.* 1991;66:1061-1064.
63. Chowdhury D, al Howasi M, Khalil M, al-Frayh AS, Chowdhury S, Ramia S. The role of bronchodilators in the management of bronchiolitis: a clinical trial. *Ann Trop Paediatr.* 1995;15:77-84.
64. Schuh S, Johnson D, Canny G, et al. Efficacy of adding nebulized ipratropium bromide to nebulized albuterol therapy in acute bronchiolitis. *Pediatrics.* 1992;90:920-923.
65. Wang EE, Milner R, Allen U, Maj H. Bronchodilators for treatment of mild bronchiolitis: a factorial randomised trial. *Arch Dis Child.* 1992;67:289-293.
66. Goebel J, Estrada B, Quinonez J, Nagji N, Sanford D, Boerth RC. Prednisolone plus albuterol versus albuterol alone in mild to moderate bronchiolitis. *Clin Pediatr.* 2000;39:213-220.
67. van Woensel JB, Kimpen JL, Sprikkelman AB, Ouwehand A, van Aalderen WM. Long-term effects of prednisolone in the acute phase of bronchiolitis caused by respiratory syncytial virus. *Pediatr Pulmonol.* 2000;30:92-96.
68. van Woensel JB, Wolfs TF, van Aalderen WM, Brand PL, Kimpen JL. Randomised double blind placebo controlled trial of prednisolone in children admitted to hospital with respiratory syncytial virus bronchiolitis. *Thorax.* 1997;52:634-637.
69. Klassen TP, Sutcliffe T, Watters LK, Wells GA, Allen UD, Li MM. Dexamethasone in salbutamol-treated inpatients with acute bronchiolitis: a randomized, controlled trial. *J Pediatr.* 1997;130:191-196.
70. Berger I, Argaman Z, Schwartz SB, et al. Efficacy of corticosteroids in acute bronchiolitis: short-term and long-term follow-up. *Pediatr Pulmonol.* 1998;26:162-166.
71. Cade A, Brownlee KG, Conway SP, et al. Randomised placebo controlled trial of nebulised corticosteroids in acute respiratory syncytial viral bronchiolitis. *Arch Dis Child.* 2000;82:126-130.
72. Daugbjerg P, Brenoe E, Forchhammer H, et al. A comparison between nebulized terbutaline, nebulized corticosteroid and systemic corticosteroid for acute wheezing in children up to 18 months of age. *Acta Paediatr.* 1993;82:547-51.

73. Fox GF, Everard ML, Marsh MJ, Milner AD. Randomised controlled trial of budesonide for the prevention of post-bronchiolitis wheezing. *Arch Dis Child.* 1999;80:343-347.
74. Kajosaari M, Syvanen P, Forars M, Juntunen-Backman K. Inhaled corticosteroids during and after respiratory syncytial virus-bronchiolitis may decrease subsequent asthma. *Pediatr Allergy Immunol.* 2000;11:198-202.
75. Reijonen T, Korppi M, Kuikka L, Remes K. Anti-inflammatory therapy reduces wheezing after bronchiolitis. *Arch Pediatr Adolesc Med.* 1996;150:512-517.
76. Richter H, Seddon P. Early nebulized budesonide in the treatment of bronchiolitis and the prevention of postbronchiolitic wheezing. *J Pediatr.* 1998;132:849-853.
77. Wong JY, Moon S, Beardsmore C, O'Callaghan C, Simpson H. No objective benefit from steroids inhaled via a spacer in infants recovering from bronchiolitis. *Eur Respir J.* 2000;15:388-394.
78. Everard ML, Swarbrick A, Rigby AS, Milner AD. The effect of ribavirin to treat previously healthy infants admitted with acute bronchiolitis on acute and chronic respiratory morbidity. *Respir Med.* 2001;95:275-280.
79. Guerguerian AM, Gauthier M, Lebel MH, Farrell CA, Lacroix J. Ribavirin in ventilated respiratory syncytial virus bronchiolitis. A randomized, placebo-controlled trial. *Am J Respir Crit Care Med.* 1999;160:829-834.
80. Janai HK, Stutman HR, Zaleska M, et al. Ribavirin effect on pulmonary function in young infants with respiratory syncytial virus bronchiolitis. *Pediatr Infect Dis J.* 1993;12:214-218.
81. Rodriguez WJ , Arrobo J, Fink R, Kim HW, Milburn C. Prospective follow-up and pulmonary functions from a placebo-controlled randomized trial of ribavirin therapy in respiratory syncytial virus bronchiolitis. Ribavirin Study Group. *Arch Pediatr Adolesc Med.* 1999;153:469-474.
82. Klein M. Multicenter trial of cefpodoxime proxetil vs. amoxicillin-clavulanate in acute lower respiratory tract infections in childhood. International Study Group. *Pediatr Infect Dis J.* 1995;14:S19-S22.
83. Andrade MA, Hoberman A, Glustein J, Paradise JL, Wald ER. Acute otitis media in children with bronchiolitis. *Pediatrics.* 1998;101:617-619.
84. Hollman G, Shen G, Zeng L, et al. Helium-oxygen improves Clinical Asthma Scores in children with acute bronchiolitis. *Crit Care Med.* 1998;26:1731-1736.
85. Van Bever HP , Desager KN, Pauwels JH, Wojciechowski M, Vermeire PA. Aerosolized furosemide in wheezy infants: a negative report. *Pediatr Pulmonol.* 1995;20:16-20.
86. Groothuis JR , Simoes EA, Hemming VG. Respiratory syncytial virus (RSV) infection in preterm infants and the protective effects of RSV immune globulin (RSVIG). Respiratory Syncytial Virus Immune Globulin Study Group. *Pediatrics.* 1995;95:463-467.
87. Groothuis JR , Simoes EA, Levin MJ, et al. Prophylactic administration of respiratory syncytial virus immune globulin to high-risk infants and young children. The Respiratory Syncytial Virus Immune Globulin Study Group. *N Engl J Med.* 1993;329:1524-1530.
88. Simoes EA, Sondheimer HM, Top FHJ, et al. Respiratory syncytial virus immune globulin for prophylaxis against respiratory syncytial virus disease in infants and children with congenital heart disease. The Cardiac Study Group. *J Ped.* 1998;133:492-499.
89. The PREVENT Study Group. Reduction of respiratory syncytial virus hospitalization among premature infants and infants with bronchopulmonary dysplasia using respiratory syncytial virus immune globulin prophylaxis. *Pediatrics.* 1997;99:93-99.
90. Groothuis JR . Safety and tolerance of palivizumab administration in a large Northern Hemisphere trial. Northern Hemisphere Expanded Access Study Group. *Pediatr Infect Dis J.* 2001;20:628-630.

91. The IMPact-RSV Study Group. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. *Pediatrics*. 1998;102:531-537.
92. Meissner HC, Groothuis JR, Rodriguez WJ, et al. Safety and pharmacokinetics of an intramuscular monoclonal antibody (SB 209763) against respiratory syncytial virus (RSV) in infants and young children at risk for severe RSV disease. *Antimicrob Agents Chemother*. 1999;43:1183-1188.
93. Groothuis JR , King SJ, Hogerman DA, Paradiso PR, Simoes EA. Safety and immunogenicity of a purified F protein respiratory syncytial virus (PFP-2) vaccine in seropositive children with bronchopulmonary dysplasia. *J Infect Dis*. 1998;177:467-469.
94. Piedra PA, Grace S, Jewell A, et al. Purified fusion protein vaccine protects against lower respiratory tract illness during respiratory syncytial virus season in children with cystic fibrosis. *Pediatr Infect Dis J*. 1996;15:23-31.
95. Piedra PA, Grace S, Jewell A, et al. Sequential annual administration of purified fusion protein vaccine against respiratory syncytial virus in children with cystic fibrosis. *Pediatr Infect Dis J*. 1998;17:217-224.
96. Marchetti A, Lau H, Magar R, Wang L, Devercelli G. Impact of palivizumab on expected costs of respiratory syncytial virus infection in preterm infants: potential for savings. *Clin Ther*. 1999;21:752-766.
97. Numa A. Outcome of respiratory syncytial virus infection and a cost-benefit analysis of prophylaxis. *J Paediatr Child Health*. 2000;36:422-427.
98. Schrand LM, Elliott JM, Ross MB, Bell EF, Mutnick AH. Cost-benefit analysis of RSV prophylaxis in high-risk infants. *Ann Pharmacother*. 2001;35:1186-1193.
99. Groothuis JR, Gutierrez KM, Lauer BA. Respiratory syncytial virus infection in children with bronchopulmonary dysplasia. *Pediatrics*. 1988;82:199-203.
100. Farina D, Rodriguez SP, Bauer G, et al. Respiratory syncytial virus prophylaxis: cost-effective analysis in Argentina. *Pediatr Infect Dis J*. 2002;21:287-291.
101. Sorrentino M, Powers T. Effectiveness of palivizumab: evaluation of outcomes from the 1998 to 1999 respiratory syncytial virus season. The Palivizumab Outcomes Study Group. *Pediatr Infect Dis J*. 2000;19:1068-1071.
102. Cunningham CK, McMillan JA, Gross SJ. Rehospitalization for respiratory illness in infants of less than 32 weeks' gestation. *Pediatrics*. 1991;88:527-532.
103. Paul DA, Leef KH, Chidekel A, Tran K, Eppes S, Stefano JL . Home delivery of palivizumab: outcomes and compliance in regional preterm infants. *Del Med J*. 2002;74:11-15.
104. Joffe S, Lieu T. Pallivizumab (Synagis): Counting "costs" and values. *Pediatrics*. 1999;106:1168.
105. Engle S, Newns GH. Proliferative mural bronchiolitis. *Arch Dis Child*. 1940;15:219.
106. Denny FW, Clyde WA. Acute lower respiratory tract infections in nonhospitalized children. *J Pediatr*. 1986;108:635-646.
107. Perlstein PH, Kotagal UR, Schoettker PJ, et al. Sustaining the implementation of an evidence-based guideline for bronchiolitis. *Arc Pediatr Adolesc Med*. 2000;154:1001-1007.
108. Gold M. Panel on cost-effectiveness in health and medicine. *Med Care*. 1996;34:DS197-DS199.
109. Wohl ME. Bronchiolitis. *Pediatr Ann*. 1986;15:307-309, 312-313.
110. Lowell DI, Lister G, Von Koss H, McCarthy P. Wheezing in infants: the response to epinephrine. *Pediatrics*. 1987;79:939-945.

111. Wang EE, Milner RA, Navas L, Maj H. Observer agreement for respiratory signs and oximetry in infants hospitalized with lower respiratory infections. *Am Rev Respir Dis*. 1992;145:106-109.
112. Tal A, Bavilski C, Yohai D, Bearman JE, Gorodischer R, Moses SW. Dexamethasone and salbutamol in the treatment of acute wheezing in infants. *Pediatrics*. 1983;71:13-8.
113. Tal A, Sanchez I, Pasterkamp H. Respirosonography in infants with acute bronchiolitis. *Am J Dis Child*. 1991;145:1405-1410.
114. Westley CR, Cotton EK, Brooks JG. Nebulized racemic epinephrine by IPPB for the treatment of croup: a double-blind study. *Am J Dis Child*. 1978;132:484-487.
115. Wood DW, Downes JJ, Lecks HI. A clinical scoring system for the diagnosis of respiratory failure. Preliminary report on childhood status asthmaticus. *Am J Dis Child*. 1972;123:227-228.
116. Bruhn FW, Yeager AS. Respiratory syncytial virus in early infancy. Circulating antibody and the severity of infection. *Am J Dis Child*. 1977;131:145-148.

